GENESIS CANCER CARE UK LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +14.6%

  £135,129,000 → £154,900,000

• Cash

  -30.8%

  £6,130,000 → £4,239,000

• Net assets

  -86.3%

  £13,569,000 → £1,856,000

• Employees

  +13.2%

  569 → 644

• Operating profit

  +136%

  -£15,856,000 → £5,707,000

• Profit before tax

  +34.3%

  -£22,569,000 → -£14,829,000

• Wages

  +27.3%

  £29,609,000 → £37,678,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. GENESIS CANCER CARE UK LIMITED 2015-10-06 → present
2. CANCERPARTNERSUK LIMITED 2006-05-25 → 2015-10-06
3. PIMCO 2472 LIMITED 2006-04-26 → 2006-05-25

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have performed a Going Concern assessment to determine the Company's ability to remain a Going Concern for a period of 12 months from the approval of these financial statements. Therefore, this is underpinned by the FY26 and FY27 forecast cash flows. Although the Company reports a loss for the year, this does not indicate a liquidity risk. The loss is driven mainly by non cash items, including an adverse fair value movement on a financial liability relating to a profit share arrangement in place with subsidiary oncology entities and an adverse fair value movement on a contingent consideration relating to a profit share arrangement in place with an external medical centre. The Company has been cash generative in the year and is expected to remain cash generative in future periods.”

Group structure

1. GENESIS CANCER CARE UK LIMITED · parent
   1. GCCUK Leasing Limited 100% · UK · Acquisition of clinical equipment
   2. Windsor Oncology Centre Limited 88% · UK · Facilitation of clinical co-investment
   3. Cambridge Oncology Centre Limited 76% · UK · Facilitation of clinical co-investment
   4. London Oncology & Wellbeing Centre Limited 55% · UK · Facilitation of clinical co-investment
   5. The Birmingham Prostate Clinic Ltd 100% · UK · Facilitation of clinical co-investment

Significant events

• “The Company has seen another year of strong revenue performance. The total revenue for the Company has increased 14.6% compared to the previous financial year”
• “a new Magnetic Resonance Linear Accelerator (MRL) was commissioned at our Guildford centre, with the first patient treated in July 2025 and an increase in patient volumes expected in future years.”
• “Planning permission was granted in September 2025, with the new centre expected to open in 2026.”
• “On 15 January 2025, the Group completed the refinancing of its Exit Facility term loan”
• “On 23 October 2025 a side letter was signed by both parties to extend the final repayment date of the loan to 30 October 2027.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.